COMP <GO>
IMRN vs LEXX // RSI-14 & 200D SMA MOMENTUM
Immuron Limited (NASDAQ) VS. Lexaria Bioscience Corp. (NASDAQ) • 15-METRIC TALLY: IMRN 0
— LEXX 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LEXX
LAST: $0.90 (+2.01%) • MKT CAP: $7.1M
rsi-technicals
34.8
LAST: $3.64 (+4.30%) • MKT CAP: $7.4M
rsi-technicals
48.6
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMRN VS. LEXX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMRN | LEXX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 52.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 4/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 34.8 | 48.6 | -13.80 | LEXX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.1M | $7.4M | -$249.1K | LEXX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMRN REV | LEXX REV | IMRN GROSS % | LEXX GROSS % | IMRN FCF | LEXX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $705.9K | — | 98.0% | — | -$10.5M |
| FY 2024 | — | $464.3K | — | 98.0% | — | -$5.0M |
| FY 2023 | — | $226.2K | — | — | — | -$5.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMRN // BETA —
LEXX // BETA —